Research update – ProQR
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
Search results
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
It was previously believed that female carriers of X-linked inherited retinal diseases (IRDs) like X-linked retinitis pigmentosa (RP and Choroideremia) remained unaffected by sight loss.
During our 50th anniversary year, Retina UK will be the focus of a BBC Lifeline Appeal on Sunday 16 November 2025.
We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.
Find out more about Martyn Osborne's big win on the Retina UK Lottery and why he would recommend playing.
Genes exist inside all the cells that make up your body. They contain genetic code (DNA) and provide instructions for constructing proteins, which are the building blocks of our bodies and perform a huge variety of roles.
Download copies of our Knowledge-base material
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
The collective partnership of eight of the leading charities in the sight loss sector, known for the last three years as the VI Charity Sector Partnership, has re-launched under a new identity of the ‘Vision Partnership’ with a re-invigorated purpose and new strategic focus.
Sepul Bio begins clinical trial of ultevursen for USH2A-associated RP